在接受稳定阿托伐他汀治疗的患者中，由中度CYP3A4抑制剂氟康唑引起的横纹肌溶解：一例报告及文献综述
Rhabdomyolysis caused by the moderate CYP3A4 inhibitor fluconazole in a patient on stable atorvastatin therapy: a case report and literature review.
作者信息
Hsiao S-H, Chang H-J, Hsieh T-H, Kao S-M, Yeh P-Y, Wu T-J
机构信息
Department of Pharmacy, National Cheng Kung University Hospital, Tainan, Taiwan.
Department of Internal Medicine, Medical college and Hospital, National Cheng Kung University, Tainan, Taiwan.
出版信息
J Clin Pharm Ther. 2016 Oct;41(5):575-8. doi: 10.1111/jcpt.12425. Epub 2016 Jul 19.
WHAT IS KNOWN AND OBJECTIVE
Rhabdomyolysis is a severe potential adverse drug reaction of statin therapy. We report a case of rhabdomyolysis due to drug-drug interaction (DDI) between atorvastatin and fluconazole and review the literature.
CASE SUMMARY
A 70-year-old woman received atorvastatin for hyperlipidaemia without any problem for 4 years. When intravenous fluconazole was added for treating a fungal infection, rhabdomyolysis developed 2 weeks later. Removal of atorvastatin led to the resolution of her rhabdomyolysis.
WHAT IS NEW AND CONCLUSION
Our case demonstrates that in some subjects even a moderate CYP3A4 inhibitor such as fluconazole may lead to rhabdomyolysis in subjects receiving a statin.
已知信息与目的
横纹肌溶解是他汀类药物治疗严重的潜在不良反应。我们报告一例因阿托伐他汀与氟康唑药物相互作用（DDI）导致的横纹肌溶解病例并复习相关文献。
病例摘要
一名70岁女性因高脂血症服用阿托伐他汀4年，无任何问题。当加用静脉注射氟康唑治疗真菌感染时，2周后发生横纹肌溶解。停用阿托伐他汀后横纹肌溶解症状缓解。
新发现与结论
我们的病例表明，在某些患者中，即使是像氟康唑这样的中度CYP3A4抑制剂，也可能导致接受他汀类药物治疗的患者发生横纹肌溶解。
Zotero 插件